Evidence map›Paper›PMID 21472523›Full record

ArticleJournal of the American Society for Mass Spectrometry2011

Identification of two reactive cysteine residues in the tumor suppressor protein p53 using top-down FTICR mass spectrometry.

Jenna Scotcher, David J Clarke, Stefan K Weidt, C Logan Mackay, Ted R Hupp, Peter J Sadler, Pat R R Langridge-Smith

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Covalent Modification of p53 by (ACS pharmacology & translational science · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Mass Spectrometry in Advancement of Redox Precision Medicine.Advances in experimental medicine and biology · 2019
    Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jenna ScotcherSIRCAMS, School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, UK.
David J Clarke
Stefan K Weidt
C Logan Mackay
Ted R Hupp
Peter J Sadler
Pat R R Langridge-Smith
University of Edinburgh · GBEdinburgh Cancer Research · GBUniversity of Warwick · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor suppressor p53 is a redox-regulated transcription factor involved in cell cycle arrest, apoptosis and senescence in response to multiple forms of stress, as well as many other cellular processes such as DNA repair, glycolysis, autophagy, oxidative stress and differentiation. The discovery of cysteine-targeting compounds that cause re-activation of mutant p53 and the death of tumor cells in vivo has emphasized the functional importance of p53 thiols. Using a combination of top-down and middle-down FTICR mass spectrometry, we show that of the 10 Cys residues in the core domain of wild-type p53, Cys182 and Cys277 exhibit a remarkable preference for modification by the alkylating reagent N-ethylmaleimide. The assignment of Cys182 and Cys277 as the two reactive Cys residues was confirmed by site-directed mutagenesis. Further alkylation of p53 beyond Cys182 and Cys277 was found to trigger co-operative modification of the remaining seven Cys residues and protein unfolding. This study highlights the power of top-down FTICR mass spectrometry for analysis of the cysteine reactivity and redox chemistry in multiple cysteine-containing proteins.

Indexed as

Alkylating AgentsAmino Acid SequenceCrystallography, X-RayCysteineEthylmaleimideFourier AnalysisHumansMass SpectrometryModels, MolecularMolecular Sequence DataOxidation-ReductionPeptide FragmentsProtein UnfoldingTemperatureTumor Suppressor Protein p53Alkylating AgentsCysteineEthylmaleimidePeptide FragmentsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID21472523
OpenAlexW2001313658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.